Wow, kinda surprised about all the questioning and the freak outs today.

If GC hadn't brought in someone with the caliber of experience that Dr. Charlotte Keywood has
http://ir.amarantus.com/company-news/detail/1...s-division

If GC didn't have Dr. Lowe teaming up with Dr. Keywood
If GC didn't have a detailed focused clinical program for going forward
If GC had only mentioned PD and left out AADHD
http://ir.amarantus.com/company-news/detail/1...adult-adhd

If GC hadn't Completed Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
http://ir.amarantus.com/company-news/detail/1...mpro-testr

If GC wasn't Announcing Positive MANF Ocular Toxicology Data
http://ir.amarantus.com/company-news/detail/1...ology-data

If GC couldn't secure a "partnership/MSA" with the likes of a worldwide CLIA Lab Such as ICON & Initiate THE CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
http://ir.amarantus.com/company-news/detail/1...boratories

If GC didn't Exercise the Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
http://ir.amarantus.com/company-news/detail/1...-disorders

If GC wasn't able to Enter Into Research Collaboration With the Buck Institute for Research on Aging for MANF
http://ir.amarantus.com/company-news/detail/1...g-for-manf

If GC wasn't able to Announce Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test(R)
http://ir.amarantus.com/company-news/detail/1...mpro-testr

If GC didn't start including that they have intellectual property for the diagnosis of Parkinson's disease ("NuroPro" and the discovery of neurotrophic factors ("PhenoGuard" in all of their PR's as of late

THEN I would have some concerns.

But in the last 6 weeks they are far more than meeting ANY expectations Or hopes I had when I bought in less than 6 months ago.